I will acknowledge a few positive points: PM is still in the conversation, Rett data will be released before year end, complete 2-73 will be published but no timeframe. Hopefully "super responders" will be documented to be able to compare data with other competitive therapies, two of which are finishing their phase 3 trials next year. BUT rat data is NOT IGN and the next drug is years away, but promising as far as MOA.
Market Data 
Markets 
AI
